AAGAB

Across TCGA pan-cancer cohorts, AAGAB Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AAGAB data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher AAGAB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AAGAB expression acts as an unfavorable survival marker, although some lineages such as BLCA and SCLC show a favorable association.

LUSC, BLCA, and KIRC are the cancer types where AAGAB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	24	view →
BLCA	DFS	Median	All	1.000	0.326	.027	13	view →
KIRC	OS	Median	All	0.152	0.874	<.001	12	view →
SCLC	OS	Median	III,IV	1.000	0.413	.046	7	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AAGAB–LUSC (DFS)

Open the LUSC breakdown →